RANBAXY WINS ON TWO ADDITIONAL ATORVASTATIN PATENTS IN NORWAY

Ranbaxy Laboratories Limited (RLL) announced that a Norwegian court handed down a favorable decision for Ranbaxy in its case against Pfizer, involving two patents on atorvastatin in Norway. Atorvastatin is a cholesterol-lowering drug which is marketed by Pfizer as Lipitor. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-29-2006/0004423558&EDATE=)